ArticleBlood2021
How I manage acquired pure red cell aplasia in adults.
Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Efficacy and influencing factors of immunosuppressive therapy for pure red cell aplasia: meta-analysis and systematic review.Annals of hematology · 2025Pooled it
- Sirolimus plus roxadustat synergistically enhances immunosuppression and erythropoiesis in pure red cell aplasia: a multicenter trial.Signal transduction and targeted therapy · 2026Trial
- Treatment-free survival to bortezomib combined with dexamethasone in patients with refractory/relapsed pure red cell aplasia: a prospective clinical study.Annals of medicine · 2025Trial
- Clinical heterogeneity and outcome of acquired PRCA: a multicenter European study.Blood advances · 2026Article
- Monoclonal Gammopathy as a Potential Cause of Pure Red Cell Aplasia: A Case Report and Literature Review.Cureus · 2026Article
- Immunological features of acquired pure red cell aplasia: Specific human leucocyte antigen alleles, signal transducer and activator of transcription 3 mutations and a unique T-cell receptor beta motif.British journal of haematology · 2026Article
- Decoding immune-driven erythroid failure in pure red cell aplasia.British journal of haematology · 2026Article
- Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.Leukemia · 2026Article
- Post-COVID-19 pure red cell aplasia: A case report and literature review.SAGE open medical case reports · 2026Article
- Recurrent thymoma-associated PRCA with persistent agranulocytosis: a case report and therapeutic considerations.Frontiers in oncology · 2026Article
- Article
- Case Report: From complete remission to severe anemia: pure red cell aplasia emerged after VRd regimen in multiple myeloma.Frontiers in oncology · 2026Article
- A Novel Therapeutic Strategy for Bone Marrow Failure: Niche Rejuvenation Using Costal Cartilage-Derived Stem Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Comprehensive analysis of the clinical feature, myeloid neoplasm-related gene mutation profiles and T cell diversity acquired pure red cell aplasia.Annals of hematology · 2025Article
- Anti-plasma cell therapy in patients with monoclonal gammopathy-associated refractory pure red cell aplasia: A report of three cases and literature review.Annals of hematology · 2025Review
- Sirolimus modulates the erythroid differentiation of K562 cells by upregulating SHP1.Annals of hematology · 2025Article
- Anti-thymocyte globulin in immune-mediated cytopenias: A monocentric experience and literature review.British journal of haematology · 2025Article
- [Nonspecific peripheral T cell lymphoma combined with pure red cell aplasia: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Concurrent inhibited erythropoiesis in a case of VEXAS syndrome.Annals of hematology · 2025Article
- Molecular landscape of CD8Annals of hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Pure red cell aplasia (PRCA) is a rare hematological disorder with multiple etiologies. The multifaceted nature of this disease is emphasized by the variety of concomitant clinical features. Classic idiopathic presentation aside, prompt recognition of pathogenetic clues is important because of their diagnostic and therapeutic implications. As a consequence, treatment of PRCA is diverse and strictly dependent on the presented clinical scenario. Here, we propose a series of clinical vignettes that showcase instructive representative situations derived from our routine clinical practice. Using these illustrative clinical cases, we review the diagnostic workup needed for a precise diagnosis and the currently available therapeutic options, discussing their applications in regard to the various PRCA-associated conditions and individual patients' characteristics. Finally, we propose a treatment algorithm that may offer guidance for personalized therapeutic recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.